Asset Details
Do you wish to reserve the book?
Unravelling the collateral damage of antibiotics on gut bacteria
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Unravelling the collateral damage of antibiotics on gut bacteria
Do you wish to request the book?
Unravelling the collateral damage of antibiotics on gut bacteria
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Unravelling the collateral damage of antibiotics on gut bacteria
2021
Overview
Antibiotics are used to fight pathogens but also target commensal bacteria, disturbing the composition of gut microbiota and causing dysbiosis and disease
1
. Despite this well-known collateral damage, the activity spectrum of different antibiotic classes on gut bacteria remains poorly characterized. Here we characterize further 144 antibiotics from a previous screen of more than 1,000 drugs on 38 representative human gut microbiome species
2
. Antibiotic classes exhibited distinct inhibition spectra, including generation dependence for quinolones and phylogeny independence for β-lactams. Macrolides and tetracyclines, both prototypic bacteriostatic protein synthesis inhibitors, inhibited nearly all commensals tested but also killed several species. Killed bacteria were more readily eliminated from in vitro communities than those inhibited. This species-specific killing activity challenges the long-standing distinction between bactericidal and bacteriostatic antibiotic classes and provides a possible explanation for the strong effect of macrolides on animal
3
–
5
and human
6
,
7
gut microbiomes. To mitigate this collateral damage of macrolides and tetracyclines, we screened for drugs that specifically antagonized the antibiotic activity against abundant
Bacteroides
species but not against relevant pathogens. Such antidotes selectively protected
Bacteroides
species from erythromycin treatment in human-stool-derived communities and gnotobiotic mice. These findings illluminate the activity spectra of antibiotics in commensal bacteria and suggest strategies to circumvent their adverse effects on the gut microbiota.
This study systematically profiles the activity of several classes of antibiotics on gut commensal bacteria and identifies drugs that mitigate their collateral damage on commensal bacteria without compromising their efficacy against pathogens.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 14/63
/ 38/23
/ 38/77
/ 64/60
/ Animals
/ Anti-Bacterial Agents - adverse effects
/ Anti-Bacterial Agents - classification
/ Anti-Bacterial Agents - pharmacology
/ Bacteria
/ Bacteria, Anaerobic - drug effects
/ Clostridioides difficile - drug effects
/ Damage
/ Drugs
/ E coli
/ Female
/ Gastrointestinal Microbiome - drug effects
/ Humanities and Social Sciences
/ Humans
/ Male
/ Mice
/ Science
